Rezultati pretraživanja
  1. prije 3 minute

    (-58.8% pre) Tonix Pharmaceuticals down 60% premarket on failed Tonmya study - SA

  2. prije 39 sekundi

    Gapping down: -58% -38.8%, -12.8%, -12.2%, -11.8%, -11.5%, -9%, -8.4%, -7.1%, -7.1%, -6.5%, -5.6%, -5.3%, -4.4%, -4.4%, -3.7%, -2.6%, -2.1%, -1.9%,$ LCI -1.5%, -1.4

  3. prije 15 sati
  4. Odgovor korisniku/ci

    The exploitation of US veterans by with the sole aim to enrich their executives is one of the most shameful acts I’ve ever seen in biotech.

  5. prije 1 sat

    LOSERS -60.053% -39.057% -37.279% -20.945% -12.735% -12.156% -11.426% -10.13% -7.492% -6.332% -5.634% -5.33%

  6. prije 6 sati

    On a look out. Looking for the bottom to load up, but damn look at that dip, this dip will test you. 😂 Mos def some few bag holders over here. Lol! Shit! 🙏🏻 Hang tight.

  7. prije 13 sati

    just looked. Never believe folks.

  8. prije 13 sati

    Really no surprise. This one is a track record of let downs. Sorry for bagholders...

  9. prije 13 sati

    don't look 👀 is it really this bad? they've got other drugs and it is a low float far as i remember.

    Prikaži ovu nit
  10. prije 13 sati

    Starter position, 35k @.53 avg for a bounce, sold 6k at 65, going for 75 to 85 for in next 2 days.. Might be too high tho ~1/share cash , but ~2.2 million burn. Still another ph3 indication, multiple other drugs.. might raise before readout if spending not cut

  11. prije 14 sati

    will drop below NASDAQ compliance tomorrow, ultimately leading to screw over the investors. I know why companies want to list on the NASDAQ it makes them seem like valid companies. They aren't until they make a commercial product and profits. We shouldn't discredit

    Prikaži ovu nit
  12. btfd btfd back to 1.20

  13. prije 14 sati

    -70% AH Phase 3 failed. Next data by Dec 2020 and cash runs out end of May Currently trading at $0.0006 after the reverse splits between 2017-2019 💩

  14. added 59c; more orders ready at 55, 53c Swinging..playing the dead cat bounce into coming days

  15. : New SEC Filing for TNXP: Form 8-K (No. 0001387131-20-001046):

  16. prije 15 sati

    sorry Longs.

  17. prije 15 sati

    looking bad

  18. prije 15 sati

    RECOVERY Study has Stopped Enrollment Due to Inadequate Separation from Placebo at Week-12 Based on Interim Analysis Results of the First 50% of Enrolled Participants

  19. Would say I'm surprised, but I'm not. Will check ER. Might dabble again. Maybe. 7.06 % change recently

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.